Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Nominations now open for 2026 Landmarks Illinois Richard H. Driehaus Foundation Preservation Awards

April 2, 2026

GLP-1 is rewriting retail demand: Four purchase rhythms retailers are missing

April 2, 2026

Reddit is moving on from r/all

April 2, 2026

Inc. Names Next Point LLC to Its 2026 List of the Fastest-Growing Private Companies in the Northeast

April 2, 2026

Beacon Hill Appoints Tim Barber to Lead Finance & Accounting in Charlotte

April 2, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Press Release

A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

By News RoomJanuary 6, 20263 Mins Read
A Race Against Blindness Awards Additional .1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Share
Facebook Twitter LinkedIn Pinterest Email

GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) — A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, today announced  $1.1 million in new grant funding to Axovia Therapeutics, closing a critical funding gap needed for the launch of the AXV-101 clinical trial, an investigational therapy aimed at treating vision loss associated with Bardet-Biedl Syndrome 1 (BBS1). This latest funding brings A Race Against Blindness’s total commitment for AXV-101 to $5.1 million.

The AXV-101 clinical trial received Clinical Trial Application (CTA) clearance during the third quarter of 2025. Despite this regulatory milestone, the trial could not move forward due to a remaining funding gap. The newly announced $1.1 million grant closes that gap, providing the vital funds needed to initiate the trial, which is now expected to begin in early 2026.

“This funding is a crucial milestone in bringing this investigational therapy into the clinic in the coming months,” said Prof. Phil Beales, Chief Executive Officer and Co-Founder of Axovia Therapeutics. “Our planned clinical trial is a first-in-human open-label dose-escalation trial, and as such, we’re moving forward with both urgency and care. We know how much uncertainty families face when they hear this diagnosis. Our goal is simple but powerful: to carefully explore whether this gene therapy can stop retinal degeneration, and, in time, change what it means to live with BBS1-related vision loss.”

A Race Against Blindness has played a central role in funding the advancement of AXV-101 from preclinical development through Clinical Trial Application (CTA) clearance, exemplifying its mission-driven approach to accelerating therapies for rare pediatric eye diseases.

“This commitment reflects our belief that promising therapies should not stall at the threshold of human trials due to lack of funding,” said Stephen Johnston, MD, MBA, Co-Founder of A Race Against Blindness. “This has been a deeply personal mission over the last 3 years, and to now be at this milestone leaves me full of gratitude and hope. The generosity of our supporters is both humbling and a beacon of light for what can be accomplished when people come together around a cause.”

About A Race Against Blindness

A Race Against Blindness is a family-run nonprofit founded by Stephen and Kristina Johnston after learning that their son has Retinitis Pigmentosa caused by Bardet-Biedl Syndrome, a rare condition leading to progressive vision loss in children. Their family has transformed a personal diagnosis into a mission to accelerate treatments for blinding diseases. Established to address the critical gap that often prevents promising vision therapies from reaching patients, A Race Against Blindness provides targeted, milestone-driven funding to move high-impact programs from the laboratory into human clinical trials.

Contact:

Dr. Stephen Johnston

Co-Founder & President

A Race Against Blindness

Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7487533c-7966-4edf-a94c-662278b9a14d

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Nominations now open for 2026 Landmarks Illinois Richard H. Driehaus Foundation Preservation Awards

GLP-1 is rewriting retail demand: Four purchase rhythms retailers are missing

Inc. Names Next Point LLC to Its 2026 List of the Fastest-Growing Private Companies in the Northeast

Beacon Hill Appoints Tim Barber to Lead Finance & Accounting in Charlotte

TDECU Cares Foundation Supports Nonprofits Meeting Critical Needs

Middle Office Outsourcing Market Analysis and Investment Forecast 2026-2034: Portfolio Management Leads the Way

NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape

IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Editors Picks

GLP-1 is rewriting retail demand: Four purchase rhythms retailers are missing

April 2, 2026

Reddit is moving on from r/all

April 2, 2026

Inc. Names Next Point LLC to Its 2026 List of the Fastest-Growing Private Companies in the Northeast

April 2, 2026

Beacon Hill Appoints Tim Barber to Lead Finance & Accounting in Charlotte

April 2, 2026

Latest News

TDECU Cares Foundation Supports Nonprofits Meeting Critical Needs

April 2, 2026

Middle Office Outsourcing Market Analysis and Investment Forecast 2026-2034: Portfolio Management Leads the Way

April 2, 2026

NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

April 2, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version